about
Genetic and functional effects of membrane metalloendopeptidase on diabetic nephropathy developmentNew susceptibility loci associated with kidney disease in type 1 diabetes.Epigenetic analyses of the insulin-like growth factor binding protein 1 gene in type 1 diabetes and diabetic nephropathyCardiovascular Autonomic Neuropathy Is an Independent Risk Factor for Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes.Impact of the hypoxia-inducible factor-1 α (HIF1A) Pro582Ser polymorphism on diabetes nephropathy.Evaluation of IGFBP-7 DNA methylation changes and serum protein variation in Swedish subjects with and without type 2 diabetesIncreased DNA methylation levels of the insulin-like growth factor binding protein 1 gene are associated with type 2 diabetes in Swedish menEffects of osthole on migration and invasion in breast cancer cells.Gender and Age Differences in Lipid Profile Among Chinese Adults in Nanjing: a Retrospective Study of Over 230,000 Individuals from 2009 to 2015.Increased expression of adenylyl cyclase 3 in pancreatic islets and central nervous system of diabetic Goto-Kakizaki rats: a possible regulatory role in glucose homeostasis.IGF2BP2 and IGF2 genetic effects in diabetes and diabetic nephropathy.The Application of SUDOSCAN for Screening Diabetic Peripheral Neuropathy in Chinese Population Screening DPN by SUDOSCAN.Insulin Glargine Combined with Oral Antidiabetic Drugs for Asians with Type 2 Diabetes Mellitus: A Pooled Analysis to Identify Predictors of Dose and Treatment Response.Subclinical hypothyroidism is not a risk factor for polycystic ovary syndrome in obese women of reproductive age.Erythropoietin alleviates hepatic steatosis by activating SIRT1-mediated autophagy.Association of Androgen Excess with Glucose Intolerance in Women with Polycystic Ovary Syndrome.A retrospective study on association between obesity and cardiovascular risk diseases with aging in Chinese adults.Evaluation of Sox2 genetic effect on the development of type 2 diabetesComparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi
P50
Q24294603-03763F6F-9A2C-4A62-9ED5-8B8D3879DE3CQ29417066-0971EE23-0E67-4EC4-B502-1B2DDE1C607BQ33714989-ACF026CC-1C3D-437C-8D98-40D0FC1FC9BFQ33790560-1B304C13-1085-4B02-B7B4-9694566DDEDFQ36560367-B6EA1A5D-40ED-447C-887B-B791CFEE6EE6Q37280536-F2D441C2-4BFF-4E82-B406-0A01AF192317Q37350189-19A73428-7127-4103-BAF8-B550F07F861DQ39681651-FB42CF88-1E68-4F0D-A4C9-F211B4038FF5Q41998720-10FDD871-7ADF-4502-A3C5-D74B4746EDC2Q42051041-5B087344-EABE-4241-B53E-9A77293F0C9EQ46093893-027A43FB-B5F0-426A-B641-D808FE79A778Q50141014-85E9563C-BBAA-4E8D-8543-6B025871A991Q51245623-E11C3DCD-79FB-44D0-91C6-651366BB961BQ52586588-85C887A2-07FD-4F24-80F9-57CCF5B39583Q52664212-24A8AFC7-75A3-4934-B154-2E19133F3B82Q53690282-9F510F57-82C2-4745-B871-6F05E621AE8CQ55443132-8C546F98-BA3B-483A-92C8-CB628ED73CFBQ58329676-356F82B8-5E06-4961-87B2-5D4BFC79BAC8Q90297993-523D3F32-B35F-425E-A431-7BC4A41ADC6D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Tianwei Gu
@ast
Tianwei Gu
@en
Tianwei Gu
@es
Tianwei Gu
@nl
Tianwei Gu
@sl
type
label
Tianwei Gu
@ast
Tianwei Gu
@en
Tianwei Gu
@es
Tianwei Gu
@nl
Tianwei Gu
@sl
prefLabel
Tianwei Gu
@ast
Tianwei Gu
@en
Tianwei Gu
@es
Tianwei Gu
@nl
Tianwei Gu
@sl
P106
P21
P31
P496
0000-0002-2320-5100
P569
2000-01-01T00:00:00Z